Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, by Drug Class (Bronchodilators (Beta 2-Agonists, Anticholinergics, Theophyllines), Phosphodiesterase Type 4 Inhibitors, Steroids, and Others), by Route of Administration (Oral and Inhalation),

Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, by Drug Class (Bronchodilators (Beta 2-Agonists, Anticholinergics, Theophyllines), Phosphodiesterase Type 4 Inhibitors, Steroids, and Others), by Route of Administration (Oral and Inhalation), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Chronic obstructive pulmonary disease (COPD) involves lung inflammation, causing obstruction of airflow from the lungs. It is a chronic disease and its symptoms include difficulty in breathing, mucus formation, wheezing, and others. COPD is a progressive lung disease, which includes chronic bronchitis, emphysema, and refractory asthma. Prime causes behind occurrence of chronic obstructive pulmonary disease include smoking, air pollution, secondhand smoke, alpha-1 deficiency-related emphysema (rare form of COPD), and others. There are certain ways, by which complications can be prevented, as well as disease progression can be slowed down. These may include quitting smoking, adherence to the prescribed medication, and preventing associated co-morbidities such as flu, pneumonia, and others by vaccination against these diseases. The two primary types of COPD are emphysema and chronic bronchitis. The four stages of chronic obstructive pulmonary disease (COPD) range from mild to very severe. Some symptoms may include an ongoing cough, shortness of breath, and wheezing. Chronic obstructive pulmonary disease (COPD) is a chronic inflammatory lung disease that causes obstructed airflow from the lungs. Symptoms include breathing difficulty, cough, mucus (sputum) production and wheezing. It is typically caused by long-term exposure to irritating gases or particulate matter, most often from cigarette smoke. Chronic bronchitis is inflammation of the lining of the bronchial tubes, which carry air to and from the air sacs (alveoli) of the lungs. It is characterized by daily cough and mucus (sputum) production.

Market Dynamics

Key players in market are involved in improving overall chronic obstructive pulmonary disease (COPD) treatment paradigm by introducing medical devices, web-based applications, and other efforts to reduce the global burden of chronic obstructive pulmonary disease, which is expected to drive the market growth over the forecast period. For instance, in May 2019, Spire Health, a healthcare company launched a study to develop new digital biomarkers that can predict exacerbations and potentially hospitalizations in patients with severe Chronic Obstructive Pulmonary Disease.

Factors such as awareness initiatives by organizations, increasing prevalence of COPD, and product launches are driving the global chronic obstructive pulmonary disease (COPD) treatment market growth. For instance, in May 2019, Boehringer Ingelheim and Optimum Patient Care announced the creation of a new patient registry, APEX COPD, to better understand COPD and how it can be typically treated in primary care offices. Such initiatives by market players are expected to boost the global chronic obstructive pulmonary disease (COPD) treatment market growth over the forecast period. Moreover, pipeline for respiratory diseases and mainly COPD has several potential medications, which is expected to drive global chronic obstructive pulmonary disease (COPD) treatment market growth.

Key features of the study:

• This report provides an in-depth analysis of the global chronic obstructive pulmonary disease (COPD) treatment market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022–2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global chronic obstructive pulmonary disease (COPD) treatment market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include AstraZeneca Plc, Orion Corporation, Mylan N.V., Boehringer Ingelheim, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Novartis AG, Sunovion Pharmaceuticals, Inc., and CHIESI Farmaceutici SpA.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global chronic obstructive pulmonary disease (COPD) treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global chronic obstructive pulmonary disease (COPD) treatment market

Detailed Segmentation:

• Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Drug Class:
• Bronchodilators
• Beta 2-Agonists
• Anticholinergics
• Theophyllines
• Phosphodiesterase Type 4 Inhibitors
• Steroids
• Others
• Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Route of Administration:
• Oral
• Inhalation
• Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Distribution Channel:
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Global Chronic Obstructive Pulmonary Disease (COPD) Treatment Market, By Region:
• North America
• By Country
• U.S.
• Canada
• Latin America
• By Country
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
• By Country
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• By Country
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• By Country
• GCC
• Israel
• Rest of Middle East
• Africa
• By Region/Country
• South Africa
• Central Africa
• North Africa
• Company Profiles
• AstraZeneca Plc*
• Company Highlights
• Products Portfolio
• Key Highlights
• Financial Performance
• Strategies
• Orion Corporation
• Mylan N.V.
• Boehringer Ingelheim
• Teva Pharmaceutical Industries Ltd.
• GlaxoSmithKline pl
• Novartis AG
• Sunovion Pharmaceuticals, Inc.
• CHIESI Farmaceutici SpA

“*” marked represents similar segmentation in other categories in the respective section.